US FDA approves the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia

Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news